Chagas disease

@article{Rassi2010ChagasD,
  title={Chagas disease},
  author={A. Rassi and J. Marin-Neto},
  journal={The Lancet},
  year={2010},
  volume={375},
  pages={1388-1402}
}
Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909. The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both. In the past three decades, the control and management of Chagas disease has undergone several improvements. Large-scale vector control programmes and screening of blood donors have reduced disease incidence and… Expand

Paper Mentions

Interventional Clinical Trial
Chagas disease (CD) is an endemic zoonotic disease with a significant global impact. Current approved treatments for CD (benznidazole (BZN) and nifurtimox (NFX)) were developed in the… Expand
ConditionsChagas Disease, Trypanosoma Cruzi Infection
InterventionDrug
Interventional Clinical Trial
This study focuses on the evaluation of low doses (600 and 1200 mg) and short treatment duration (at 3, 7 and 10 days) of fexinidazole (Fexi) to determine the minimal efficacious… Expand
ConditionsChagas' Disease (Chronic) Nos
InterventionDrug
Chagas Disease: Chronic Chagas Cardiomyopathy.
TLDR
Chagas disease is the leading cause of nonischemic cardiomyopathy (NICM) in Latin America and affects around 30% of infected patients, leading to a highly arrhythmogenic disease. Expand
Congenital transmission of Chagas disease - Virginia, 2010.
TLDR
The first case of congenital Chagas disease in the United States confirmed by CDC is described and the importance of raising awareness of ChagAs disease among health-care providers is highlighted. Expand
Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
TLDR
Low quality of the evidence suggests that there may be a benefit of benznidazole when compared to placebo for clearance or reduction of antibody titres, but there is insufficient evidence to support the efficacy of the trypanocidal drugs. Expand
Review of Chagas Disease and Treatment Obstacles to Eradication
TLDR
Although research has led to several advances in the knowledge of CD, there are gaps in treatment and epidemiological research, leaving millions of people susceptible to infection. Expand
Imaging the development of chronic Chagas disease after oral transmission
TLDR
The oral route neither exacerbates nor ameliorates experimental Chagas disease, and chronic phase parasite load profiles, tissue distribution and myocardial fibrosis severity were comparable to needle-injected controls. Expand
[Postpartum treatment without interrupting breastfeeding in a patient with Chagas disease].
TLDR
A case of a 24-year-old who was diagnosed with Chagas disease by donating blood and confirmed by the State Laboratory of Public Health, and treating the mother began with benznidazole for 45 days, which was well tolerated, but the patient remained seropositive. Expand
Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis
TLDR
T. cruzi infection results in changes in the gut microbiome that may play a role in the myocardial and intestinal inflammation seen in Chagas disease, and the QIIME platform was used to analyze the data. Expand
An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases
TLDR
Several target-based drug candidates targeting sterol biosynthetic pathway (C14-ademethylase), L-cysteine protease, heme peroxidation, mitochondria, farnesyl pyrophosphate, etc., which are vital and unique to the causative parasite are discussed. Expand
Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening
TLDR
It is found that a congenital Chagas screening program in the United States is cost saving for all rates of congenital transmission greater than 0.001% and all levels of maternal prevalence greater than0.06% compared with no screening program. Expand
DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
TLDR
The pBCSSP4 plasmid had a better effect on most of the parameters evaluated in this study and can be considered an optional treatment against Chagas disease in naturally infected dogs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease
TLDR
In patients with established chronic disease, several pharmacological and non-pharmacological interventions are currently available and have been increasingly used with the intention of preventing or delaying complications of the disease (tertiary prevention), and this review discusses in detail each of these issues. Expand
Chagas' Heart Disease
TLDR
The use of amiodarone, angiotensin‐converting enzyme inhibitors, and pacemaker implantation may contribute to a better survival in selected patients with cardiac involvement of chronic Chagas' disease. Expand
Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy.
TLDR
The cost-benefit analysis of investment in the vector control programme in Brazil indicates that there are savings of US$17 in medical care and disabilities for each dollar spent on prevention, showing that the programme is a health investment with very high return. Expand
Chagas cardiomyopathy: Europe is not spared!
TLDR
The compelling arguments by which chagasic cardiomyopathy should be moved upfront in the mindset of European cardiologists, actively looked for, and appropriately recognized are reviewed. Expand
Mechanisms of pathogenesis in Chagas disease
TLDR
This article excludes the autoimmunity hypothesis for Chagas disease because it has been extensively reviewed elsewhere, and summarizes the various alternative hypotheses that have been advanced over the years and an outline of its main tenets and key findings that support them is presented. Expand
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities
TLDR
The efficacy and tolerance of benznidazole is inversely related to the age of the patient, while its side effects are more frequent in elderly patients, which means that the true clinical impact of the side effects could be different. Expand
Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS
Abstract Between June 1989 and December 2005, an observational study of adults co-infected with HIV and Trypanosoma cruzi was conducted, to investigate the spectrum of manifestations of chronicExpand
Chagas disease and the US blood supply
TLDR
Based on recent data, antitrypanosomal treatment is recommended for all acute and congenital T. cruzi infections, reactivated infection, and chronically infected children and in adults aged 19–50 years without advanced heart disease, treatment should generally be offered. Expand
Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery.
TLDR
Control of Chagas disease must be undertaken by interrupting its transmission by vectors and blood transfusions, improving housing and areas surrounding dwellings, providing sanitation education for exposed populations and treating acute and recently infected chronic cases. Expand
Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification.
TLDR
The pathophysiology of myocardial damage is reviewed, the value of current risk stratification models are discussed and an algorithm to guide mortality risk assessment and therapeutic decision-making in patients with CHD is proposed. Expand
...
1
2
3
4
5
...